Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Autor: Sonja Zweegman, Zweegman, Claudia A M Stege, A, Haukås, Einar, Schjesvold, Fredrik H, Mark-David Levin, Levin, Waage, Anders, Rineke B L Leys, B, Saskia K Klein, K, Szatkowski, Damian Lukasz, Per Axelsson, Axelsson, Trung Hieu Do, Hieu, Dorota Knut-Bojanowska, Knut-Bojanowska, Ellen van der Spek, van, Asta Svirskaite, Svirskaite, Anja Klostergaard, Klostergaard, Morten Salomo, Salomo, Celine Blimark, Blimark, Paula F Ypma, F, Ulf-Henrik Mellqvist, Mellqvist, Pino J Poddighe, J, Marian Stevens-Kroef, Stevens-Kroef, Niels W C J van de Donk, W, Pieter Sonneveld, Sonneveld, Markus Hansson, Hansson, Bronno van der Holt, van, Niels Abildgaard, Abildgaard

Publikováno v: Sonja Zweegman, Zweegman Claudia A M Stege, A Haukås, Einar Schjesvold, Fredrik H Mark-David Levin, Levin Waage, Anders Rineke B L Leys, B Saskia K Klein, K Szatkowski, Damian Lukasz Per Axelsson, Axelsson Trung Hieu Do, Hieu Dorota Knut-Bojanowska, Knut-Bojanowska Ellen van der Spek, van Asta Svirskaite, Svirskaite Anja Klostergaard, Klostergaard Morten Salomo, Salomo Celine Blimark, Blimark Paula F Ypma, F Ulf-Henrik Mellqvist, Mellqvist Pino J Poddighe, J Marian Stevens-Kroef, Stevens-Kroef Niels W C J van de Donk, W Pieter Sonneveld, Sonneveld Markus Hansson, Hansson Bronno van der Holt, van Niels Abildgaard, Abildgaard . Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. 2020, 105(12), 2879-2882
Haematologica

Externí odkaz: http://hdl.handle.net/10852/82757
https://www.duo.uio.no/bitstream/handle/10852/82757/1/Ixazomib-Thalidomide-low%2Bdose%2Bdexamethasone%2Binduction%2Bfollowed%2Bby%2Bmaintenance%2Btherapy%2Bwith%2Bixazomib%2Bor%2Bplacebo%2Bin%2Bnewly%2Bdiagnosed%2Bmultiple%2Bmyeloma%2Bpatients%2Bnot%2Beligible%2Bfor%2Bautologous%2Bstem%2Bcell%2Btransplantation.pdf